Proteinuria and its consequences in renal disease

Acta Paediatrica, International Journal of Paediatrics, Supplement

Volumn 92, Issue 443, 2003, Pages 9-13

  Schieppati, A ^a,b   Remuzzi, G ^a,b,c  

^a Clinical Research Center for Rare Diseases   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Chronic renal disease; Fabry disease; Proteinuria; Renal pathology

Indexed keywords

ACID; AMMONIA; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CYTOKINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENZYME; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PLACEBO; PROTON; RAMIPRIL; RANTES; STATIN; TRANSFERRIN; VERAPAMIL;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CELL VACUOLE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; DIET; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DYSLIPIDEMIA; ENZYME REPLACEMENT; EPITHELIUM CELL; FABRY DISEASE; GLOMERULUS; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEALING; HEMODYNAMICS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTROPHY; INTRAGLOMERULAR HYPERTENSION; INTRAGLOMERULAR HYPERTROPHY; KIDNEY DISEASE; KIDNEY DISTAL TUBULE; KIDNEY FUNCTION; KIDNEY INJURY; LIPID STORAGE; LYSOSOME STORAGE DISEASE; MESANGIUM CELL; METABOLIC ACIDOSIS; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; PROTECTION; PROTEIN RESTRICTION; PROTEIN URINE LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOKING CESSATION; URINARY EXCRETION; VASOCONSTRICTION; X CHROMOSOME LINKED DISORDER;

EID: 1642455941     PISSN: 08035326     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2003.tb00213.x     Document Type: Conference Paper

References (41)

1. Anderson W. A case of "ansiokeratoma". Br J Dermatol 1898; 10: 113-7
2. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-38
3. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002; 13 Suppl 2: S134-8
4. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-56
5. Rennke HG, Anderson S, Brenner BM. Structural and functional correlations in the progression of renal disease. In: Tisher CC, Brenner BM. Renal Pathology. Philadelphia: Lippincott; 1989: 43-66
6. Hayslett JP. Functional adaptation to reduction in renal mass. Physiol Rev 1979; 59: 137-64
7. Johnson HA, Vera Roman JM. Compensatory renal enlargement. Hypertrophy versus hyperplasia. Am J Pathol 1966; 49: 1-13
8. Anderson S, Meyer TW, Brenner BM. The role of hemodynamic factors in the initiation and progression of renal disease. J Urol 1985; 133: 363-8
9. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982; 307: 652-9
10. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996; 7: 653-60
11. Bohrer MP, Deen WM, Robertson CR, Brenner BM. Mechanism of angiotensin II-induced proteinuria in the rat. Am J Physiol 1977: 233: F13-21
12. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998; 53: 1608-15
13. Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G. Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986; 30: 488-96
14. Bertani T, Zoja C, Abbate M, Rossini M, Remuzzi G. Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein content. Lab Invest 1989: 60: 196-204
15. Eddy AA. Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 1989; 135: 719-33
16. Alfrey AC, Froment DH, Hammond WS. Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 1989; 36: 753-9
17. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int 1992; 42: 148-60
18. Rennke HG. How does glomerular epithelial cell injury contribute to progressive glomerular damage? Kidney Int Suppl 1994; 45: S58-63
19. Cortes P, Riser BL, Yee J, Narins RG. Mechanical strain of glomerular mesangial cells in the pathogenesis of glomerulosclerosis: clinical implications. Nephrol Dial Transplant 1999; 14: 1351-4
20. Shankland SJ, Ly H, Thai K, Scholey JW. Increased glomerular capillary pressure alters glomerular cytokine expression. Circ Res 1994; 75: 844-53
21. Taal MW, Brenner BM. Achieving maximal renal protection in nondiabetic chronic renal disease. Am J Kidney Dis 2001; 38: 1365-71
22. Keane WF. Lipids and the kidney. Kidney Int 1994; 46: 910-20
23. Diamond JR, Karnovsky MJ. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int 1987; 32: 671-7
24. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601-8
25. Rubin R, Silbiger S, Sablay L, Neugarten J. Combined anti-hypertensive and lipid-lowering therapy in experimental glomerulonephritis. Hypertension 1994; 23: 92-5
26. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P. et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997; 20: 1891-5
27. Massy ZA, Khoa TN, Lacour B, Descamps-Latscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999: 14: 2392-7
28. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-9
29. Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985; 76: 667-75
30. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-62
31. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 1998; 53: 1209-16
32. Campbell RC, Ruggenenti P, Remuzzi G. Halting the progression of chronic nephropathy. J Am Soc Nephrol 2002; 13 Suppl 3: S190-5
33. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976; 36: 383-8
34. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996: 334: 13-18
35. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1: 581-4
36. Aros C, Remuzzi G. The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens 2002; 20 Suppl 3: S45-53
37. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53
38. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-24
39. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998; 31: 954-61
40. Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 2002; 13 Suppl 2: S139-43
41. De Schoenmakere G, Chauveau D, Grünfeld JP. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 2003; 18: 33-5